Dosing & Uses
AdultPediatric
Dosage Forms & Strengths
nasal spray
- 0.125%
- 0.25%
- 0.5%
- 1%
Nasal Congestion
Instill 2-3 sprays or 2-3 gtt q4hr of 0.25-0.1% solution PRN; not to exceed 3 days
Dosage Forms & Strengths
nasal spray
- 0.125%
- 0.25%
- 0.5%
- 1%
Nasal Congestion
<2 years
- Consult a physician
2-6 years
- 1-3 gtt intranasally q2-4hr of 0.125% solution PRN; not to exceed 3 days
6-12 years
- 2-3 gtt intranasally q4hr of 0.25% solution PRN; not to exceed 3 days
>12 years old
- Instill 1-2 sprays or 1-2 gtt intranasally q4hr of 0.25-0.1% solution PRN; not to exceed 3 days
Next:
Interactions
Interaction Checker
and phenylephrine nasal
No Results
No Interactions Found
Interactions Found
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
All Interactions Sort By:
Previous
Next:
Adverse Effects
Frequency Not Defined
Stinging
Dryness
Rebound congestion
Sneezing
Burning
Previous
Next:
Warnings
Contraindications
Cardiac disease (hypertension, HR, palpitations)
Nonselective MAO inhibitors: Risk of hypertensive reaction
Cautions
Rebound congestion may occur
Use caution in DM and hypertension
Previous
Next:
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Previous
Next:
Pharmacology
Mechanism of Action
Alpha adrenergic agonist; stimulates alpha-adrenergic receptors in nasal conjunctiva and arterioles to produce vasoconstriction that results in nasal decongestion
Pharmacokinetics
Absorption: Minimal systemic
Duration: 2.5 - 4 hr
Onset: < 2 min
Previous
Next:
Images
Previous
Next:
Patient Handout
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
